Zydus Lifesciences has received US FDA priority review for its liver disease drug, Saroglitazar, with a target approval date in November 2026. The company is also scaling its US oncology presence through the $166.4 million acquisition of Assertio Holdings. Investors are watching how these initiatives, alongside efforts to address US drug shortages, will impact the company's financial growth.
What Happened
Zydus Lifesciences has moved closer to a potential launch for its liver disease treatment, Saroglitazar magnesium. The US Food and Drug Administration (FDA) has granted a priority review for the company’s new drug application. This move is significant because a priority review shortens the evaluation time, reflecting the drug's potential importance in treating Primary Biliary Cholangitis (PBC). The FDA has set a target action date of November 27, 2026, for a decision. If approved, the company aims to launch the product in the US market by the fourth quarter of the 2027 fiscal year.
Strategic Oncology Focus
Beyond liver disease, Zydus is actively expanding its presence in the US oncology market. The company recently completed a $166.4 million acquisition of Assertio Holdings to build a stronger commercial platform. This deal focuses on products like Rolvedon, a biologic for chemotherapy patients.
Zydus is also benefiting from ongoing supply constraints in the US for certain oncology drugs. With major suppliers like Baxter International warning that shortages of drugs like ifosfamide may persist until early 2027, Zydus has positioned itself as a key alternative supplier. This situation highlights the company's ability to fill gaps in the US specialty drug market, which is a major part of its medium-term growth strategy.
Financial Targets and Expansion
The company has outlined a clear financial roadmap for the coming year. Management expects revenue growth in the high-teen percentage range for FY27, with operating profit margins (EBITDA margins) projected to exceed 24%. To support this, Zydus has planned capital spending of Rs 1,500 crore for FY27. A significant portion of this growth is expected to come from its domestic Indian business, which the company anticipates will outperform the broader industry growth by 200-400 basis points.
Pipeline and Market Competition
The road ahead for Saroglitazar involves competing with well-established therapies from global players like Gilead and Ipsen. Success will depend on the company's ability to capture market share in a competitive environment.
Zydus also holds high hopes for its drug Desidustat, which treats anemia in chronic kidney disease patients. It is already approved in India and China. In the US, the drug has received Orphan Drug Designation for Sickle Cell Disease, which provides seven years of market exclusivity upon approval, along with tax benefits. This adds a layer of long-term potential to the company’s novel drug portfolio.
Risks and Valuation
While the expansion plans are ambitious, investors should consider the risks inherent in pharmaceutical development. The Saroglitazar launch depends on regulatory approval, which is never guaranteed. Additionally, integrating the newly acquired Assertio business and managing the competitive landscape in the US market are key tasks for management.
From a valuation perspective, the stock is currently trading at 13.4 times its projected EV/EBITDA for FY28. This metric helps investors understand the company's value relative to its estimated operating earnings.
What Investors Should Track
Moving forward, the key dates and monitorables include the November 27, 2026, target decision date for Saroglitazar. Investors will also look for updates on the integration of Assertio and whether the company can maintain its margin targets above 24% amidst the planned capital spending. Performance in the US oncology business and the speed of the Saroglitazar launch will be vital indicators of the company’s success in its high-value specialty drug strategy.